Phase II study of carboplatin-gemcitabine combination chemotherapy in elderly patients with advanced non–small cell lung cancer
Not Applicable
- Conditions
- non small cell lung cancer
- Registration Number
- JPRN-C000000112
- Lead Sponsor
- Kumamoto University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
Individuals with active infection, severe heart disease, active concomitant malignancy, or pleural or pericardial effusion requiring drainage were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does carboplatin-gemcitabine combination therapy impact DNA repair pathways in elderly NSCLC patients?
What is the comparative effectiveness of carboplatin-gemcitabine versus standard-of-care regimens for advanced NSCLC in the elderly?
Which biomarkers correlate with response to carboplatin-gemcitabine in JPRN-C000000112's elderly NSCLC cohort?
What are the toxicity profiles and management strategies for carboplatin-gemcitabine in elderly NSCLC populations?
Are there alternative platinum-based combinations or immunotherapies for advanced NSCLC in elderly patients?